factor viia

Summary

Summary: Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.

Top Publications

  1. ncbi rFVIIai in Acute Coronary Syndromes
    Brit Binow Sorensen
    Haemostasis Biology, Novo Nordisk A/S, , Denmark
    Semin Vasc Med 3:199-204. 2003
  2. ncbi Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells
    Xiaofeng Jiang
    Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street Room 300 OMS, Philadelphia, PA 19140, USA
    Thromb Haemost 100:127-33. 2008
  3. ncbi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
  4. ncbi Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
    Todd A Hembrough
    EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
    Cancer Res 63:2997-3000. 2003
  5. ncbi Structure of human factor VIIa and its implications for the triggering of blood coagulation
    A C Pike
    Structural Biology Laboratory, Chemistry Department, University of York, York YO10 5DD, United Kingdom
    Proc Natl Acad Sci U S A 96:8925-30. 1999
  6. ncbi Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial
    Barton Sachs
    Texas Back Institute Clinical Research Organization, Plano, TX, USA
    Spine (Phila Pa 1976) 32:2285-93. 2007
  7. ncbi First 20 years with recombinant FVIIa (NovoSeven)
    U Hedner
    Department of Medicine, University of Lund, Lund, Sweden
    Haemophilia 17:e172-82. 2011
  8. ncbi Recombinant factor VIIa: its background, development and clinical use
    Ulla Hedner
    University of Lund, Sweden
    Curr Opin Hematol 14:225-9. 2007
  9. ncbi Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects
    Evert de Jonge
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Clin Diagn Lab Immunol 10:495-7. 2003
  10. ncbi Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006

Research Grants

  1. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
  2. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
  3. Tissue Factor Pathway Inhibitor Binding Proteins on Endo
    ALAN MAST; Fiscal Year: 2005
  4. BIOCHEMISTRY OF VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1990
  5. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 2001
  6. FACTOR XI PHYSIOLOGY AND MOLECULAR BIOLOGY
    David Gailani; Fiscal Year: 2000
  7. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
  8. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1993
  9. Studies of rHuTPO in ITP and of rVlla in Liver Disease
    David Kuter; Fiscal Year: 2006
  10. Deoxyribozymes for Bioorganic Chemistry
    Scott K Silverman; Fiscal Year: 2010

Detail Information

Publications186 found, 100 shown here

  1. ncbi rFVIIai in Acute Coronary Syndromes
    Brit Binow Sorensen
    Haemostasis Biology, Novo Nordisk A/S, , Denmark
    Semin Vasc Med 3:199-204. 2003
    ..In a limited number of patients undergoing percutaneous transluminal coronary angioplasty (PTCA), rFVIIai was observed to allow PTCA to be performed at lower doses of heparin than what has been reported previously...
  2. ncbi Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells
    Xiaofeng Jiang
    Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street Room 300 OMS, Philadelphia, PA 19140, USA
    Thromb Haemost 100:127-33. 2008
    ..Targeting the TF-mediated cell signaling pathway might represent a novel strategy for the treatment of breast cancer...
  3. ncbi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
    Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.
  4. ncbi Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
    Todd A Hembrough
    EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
    Cancer Res 63:2997-3000. 2003
    ..coagulation on tumor growth, in vivo, we tested coagulation inhibitors specific for either tissue factor (TF)/factor VIIa (fVIIa) complexes or factor Xa (fXa) for antitumor activity...
  5. ncbi Structure of human factor VIIa and its implications for the triggering of blood coagulation
    A C Pike
    Structural Biology Laboratory, Chemistry Department, University of York, York YO10 5DD, United Kingdom
    Proc Natl Acad Sci U S A 96:8925-30. 1999
    b>Factor VIIa (EC 3.4.21.21) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade. On injury, factor VIIa forms a complex with its allosteric regulator, tissue factor, and initiates blood clotting...
  6. ncbi Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial
    Barton Sachs
    Texas Back Institute Clinical Research Organization, Plano, TX, USA
    Spine (Phila Pa 1976) 32:2285-93. 2007
    ..Randomized, placebo-controlled, double-blind, multicenter, Phase IIa study...
  7. ncbi First 20 years with recombinant FVIIa (NovoSeven)
    U Hedner
    Department of Medicine, University of Lund, Lund, Sweden
    Haemophilia 17:e172-82. 2011
    ..By exploiting this mechanism of action, rFVIIa may also be effective in situations other than haemophilia, characterized by an impaired thrombin generation...
  8. ncbi Recombinant factor VIIa: its background, development and clinical use
    Ulla Hedner
    University of Lund, Sweden
    Curr Opin Hematol 14:225-9. 2007
    ..For the first time it was shown that pharmacological doses of FVIIa induced hemostasis...
  9. ncbi Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects
    Evert de Jonge
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Clin Diagn Lab Immunol 10:495-7. 2003
    ..we report that the activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of interleukin 6 (IL-6) and IL-8 in plasma...
  10. ncbi Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006
    We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with ..
  11. ncbi Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    B Siegmund
    Haemophilia 11:638-41. 2005
  12. ncbi Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor
    P Laguna
    Department of Paediatrics, Haematology, and Oncology, Warsaw Medical University, Poland
    Haemophilia 11:2-4. 2005
    ..Duration in the therapy and intervals between rFVIIa doses depended on the severity of bleeding. rFVIIa was proven to be highly effective and no side-effects of the product were observed...
  13. ncbi Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries
    P O Bonnet
    Medical Outcomes Research and Economics, Baxter BioScience, One Baxter Way, Westlake Village, CA, USA
    Haemophilia 15:1083-9. 2009
    ..This study assessed the cost of FEIBA, an activated prothrombin complex concentrate and recombinant factor VIIa (rFVIIa) when used in inhibitor patients undergoing major surgeries...
  14. ncbi Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
    P Salaj
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Haemophilia 15:752-9. 2009
    ..This registry has provided a unique insight into the bleeding patterns of inhibitor patients, highlighting the importance of early treatment initiation and appropriate starting dose...
  15. ncbi A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo
    Alan G Olivero
    Department of Medicinal Chemistry, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:9160-9. 2005
    The serine protease factor VIIa (FVIIa) in complex with its cellular cofactor tissue factor (TF) initiates the blood coagulation reactions. TF...
  16. ncbi Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage
    A Shaun Rowe
    Department of Pharmacy, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA
    Am J Health Syst Pharm 67:361-5. 2010
    The use of coagulation factor VIIa (recombinant) for the treatment of warfarin-induced intracranial hemorrhage (ICH) is described.
  17. ncbi Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux
    T Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center, Utrecht, The Netherlands
    J Thromb Haemost 1:2368-73. 2003
    ..Recently, it was shown that recombinant FVIIa (rFVIIa) reverses anticoagulant effects of fondaparinux in healthy volunteers...
  18. ncbi Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa
    Andrew Dao
    Department of Internal Medicine, California Pacific Medical Center, San Francisco, Calif, USA
    Am J Med 118:1172-3. 2005
  19. ncbi Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage
    Frederic J Mercier
    Departement d Anesthesie Reanimation, Hopital Antoine Beclere, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique Hopitaux de Paris, Universite Paris XI, Clamart, France
    Curr Opin Anaesthesiol 23:310-6. 2010
    ..To guide the optimal use of blood products and to clarify the indications for prohemostatic drugs in obstetric hemorrhage...
  20. ncbi A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia
    Z H Yuan
    Department of Emergency, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China
    J Clin Neurosci 17:685-93. 2010
    ..In conclusion, the use of rFVIIa reduces the growth of the hematoma but does not improve patient survival or functional outcome after ICH; in addition, rFVIIa increases the incidence of arterial TAE...
  21. ncbi A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome
    Jean Louis Vincent
    Department of Intensive Care, Hopital Erasme, Universite Libre de Bruxelles, Belgium
    Crit Care Med 37:1874-80. 2009
    To evaluate the safety and efficacy of active site inactivated recombinant factor VIIa (FFR-rFVIIa) in patients with acute respiratory distress syndrome.
  22. ncbi Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
    Katrin Groebke Zbinden
    F Hoffmann La Roche Ltd, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 15:817-22. 2005
    Proof of concept experiments have shown that tissue factor/factor VIIa inhibitors have antithrombotic activity without enhancing bleeding propensity...
  23. ncbi Recombinant factor VIIa for treatment of gastrointestinal hemorrhage following rattlesnake envenomation
    Anne Michelle Ruha
    Department of Medical Toxicology, Banner Good Samaritan Medical Center, Phoenix, AZ, USA
    Wilderness Environ Med 20:156-60. 2009
    ..The man developed massive gastrointestinal hemorrhage that was ultimately treated with recombinant factor VIIa. He presented to an emergency department with a depressed level of consciousness, a blood pressure of 60/20 mm ..
  24. ncbi Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients
    Richard P Dutton
    Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Anesth 15:184-8. 2003
    STUDY OBJECTIVE: To examine our institutional experience with recombinant Factor VIIa (rFVIIa) as a treatment for exsanguinating hemorrhage in critically ill trauma patients. DESIGN: Retrospective case review...
  25. ncbi Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor
    Y Z Ohkubo
    Beckman Institute for Advanced Science and Technology, University of Illinois, Urbana, IL, USA
    J Thromb Haemost 8:1044-53. 2010
    The molecular mechanism of enhancement of the enzymatic activity of factor VIIa by tissue factor (TF) is not fully understood, primarily because of the lack of atomic models for the membrane-bound form of the TF-FVIIa complex.
  26. ncbi Recombinant factor VIIa. An update on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Thromb Haemost 93:1027-35. 2005
    ..Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications...
  27. ncbi Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery
    James Tatoulis
    Department of Cardiothoracic Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    Interact Cardiovasc Thorac Surg 9:459-62. 2009
    The aim of this case series is to review the effect of recombinant activated factor VIIa (rFVIIa) on refractory haemorrhage, despite aggressive treatment with conventional blood products and medications at our institution...
  28. ncbi Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage
    Henry R Maun
    Department of Protein Engineering, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Biol Chem 278:21823-30. 2003
    ..two distinct classes of exosite peptide inhibitors for the initiator of the clotting process, the tissue factor-factor VIIa (TF.FVIIa) complex (Roberge, M., Santell, L., Dennis, M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A...
  29. ncbi Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma
    Uri Martinowitz
    National Hemophilia Center, Tel Hashomer, Israel
    Can J Anaesth 49:S15-20. 2002
    ..It is approved for use in hemophilia patients, however, its use in trauma is still controversial due to the theoretical risk of thromboembolic complications...
  30. ncbi Recombinant coagulation factor VIIa--from molecular to clinical aspects of a versatile haemostatic agent
    Egon Persson
    Biopharmaceuticals Research Unit, Novo Nordisk A S, Måløv, Denmark
    Thromb Res 125:483-9. 2010
    Recombinant factor VIIa (rFVIIa, NovoSeven) is currently the only bypassing agent produced by recombinant technology for the treatment of haemophiliacs whose disease is complicated by inhibitory antibodies...
  31. ncbi Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors
    Chris Knight
    RTI Health Solutions, Williams House, Manchester, M15 6SE, UK
    Adv Ther 26:68-88. 2009
    ..Our aim is to establish robust estimates of the efficacy, speed of bleed resolution, and adverse event profile of both rFVIIa and aPCC...
  32. ncbi Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
    Alicia M Mohr
    Department of Surgery, New Jersey Medical School, Newark, New Jersey, USA
    Crit Care 9:S37-42. 2005
    ..Further prospective, randomized, and placebo-controlled clinical trials will yield more information on the role of rFVIIa in the management of traumatic bleeding...
  33. ncbi Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand
    Oliver Flower
    Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
    Blood Coagul Fibrinolysis 21:207-15. 2010
    Recombinant factor VIIa (rFVIIa) is used in the treatment of life-threatening haemorrhage that is refractory to conventional treatment. The evidence supporting this practice in patients with liver disease is very limited...
  34. ncbi Control of bleeding in patients with haemophilia A with inhibitors: a systematic review
    M Lloyd Jones
    ScHARR, University of Sheffield, Regent Court, Sheffield, UK
    Haemophilia 9:464-520. 2003
    ..APCCs controlled bleeding in approximately 90% of surgical episodes. Recombinant factor VIIa (rFVIIa) controlled 70-100% of mild to severe bleeding episodes with high-responding inhibitors, and achieved ..
  35. ncbi Recombinant factor VIIa in major abdominal surgery and liver transplantation
    J da Silva Viana
    Faculty of Medicine, University of Coimbra, Coimbra, Portugal
    Transplant Proc 38:818-9. 2006
    ..The majority of the reviewed investigators accepted the use of rFVIIa after or simultaneously with the use of aprotinin; no data refute the safety of this association...
  36. ncbi Recombinant-activated coagulation factor VIIa (NovoSeven): current development
    R B Weiskopf
    Novo Nordisk A S, Novo Alle, DK 2880 Bagsvaerd, Denmark
    Vox Sang 92:281-8. 2007
    ..This review summarizes the current development of rFVIIa, focusing on results of prospective, randomized clinical trials...
  37. ncbi The role of recombinant-activated factor VII in bleeding trauma patients
    Richard P Dutton
    Department of Anesthesiology, University of Maryland School of Medicine, Division of Anesthesiology, R Adams Cowley Shock Trauma Center, University of Maryland Medical System, Baltimore, Maryland 21201, USA
    Curr Opin Anaesthesiol 22:299-304. 2009
    ..Exsanguinating hemorrhage and postshock organ failure account for 35-40% of deaths from trauma, and there is an increasing recognition of the importance of coagulopathy in the evolution of this disease...
  38. ncbi Use of recombinant factor VIIA for control of combat-related haemorrhage
    Susan I Woodruff
    San Diego State University, School of Social Work, San Diego, USA
    Emerg Med J 27:121-4. 2010
    ..Recombinant activated human coagulation factor VII (rFVIIa), an intravascular strategy to promote clotting, is being used as an adjunct to surgical control of bleeding in combat trauma patients...
  39. ncbi Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time
    James A Szalony
    Department of Cardiovascular Pharmacology, Pfizer Corporation, 4901 Searle Parkway, Skokie, IL 60077, USA
    Thromb Res 112:167-74. 2003
    ..study used a non-human primate model to test the effect of PHA-798, a specific inhibitor of the tissue factor/Factor VIIa complex (TF/VIIa), on venous thrombus formation...
  40. ncbi Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa
    Mamoru Shoji
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Drug Target 16:185-97. 2008
    ..As a transmembrane receptor for coagulation factor VIIa (fVIIa), TF forms a high-affinity complex with its cognate ligand, which is subsequently internalized through ..
  41. ncbi The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
    D W Banner
    Pharma Division, F Hoffmann La Roche, Basle, Switzerland
    Nature 380:41-6. 1996
    Blood coagulation is initiated when tissue factor binds to coagulation factor VIIa to give an enzymatically active complex which then activates factors IX and X, leading to thrombin generation and clot formation...
  42. ncbi Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood
    Grigoris T Gerotziafas
    Service d Hematologie Biologique, Hopital Hotel Dieu de Paris, 1 Place du Parvis Notre Dame, 75181, Paris, Cedex 04, France
    Thromb Haemost 91:531-7. 2004
    ..The potential clinical use of rFVIIa as haemostatic treatment of major bleedings related to fondaparinux has to be evaluated...
  43. ncbi The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1
    Marvin T Nieman
    Thromgen Inc, Ann Arbor, MI 48109-0640, USA
    J Pharmacol Exp Ther 311:492-501. 2004
    ..TH146 and MAP4-TH146 inhibit both alpha-thrombin with a K(i) value of 97 and 49 microM, respectively, and factor VIIa with a K(i) value of 44 and 5 microM, respectively...
  44. ncbi In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes
    Britt Petersson
    Biopharm API and DP Support, Novo Nordisk A S, Gentofte, Denmark
    Clin Ther 30:917-23. 2008
    Recombinant activated factor VIIa (rFVIIa) is indicated for on-demand treatment of bleeding and the prevention and treatment of surgical bleeding in patients with hemophilia A or B who have antibodies to coagulation factors VIII or IX...
  45. ncbi The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface
    Cees Weeterings
    Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 112:3227-33. 2008
    Several lines of evidence suggest that recombinant factor VIIa (rFVIIa) is able to activate factor X on an activated platelet, in a tissue factor-independent manner...
  46. ncbi In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature
    Hanne Nedergaard
    Pharmaceutics, BIOPHARM, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Ther 30:1309-15. 2008
    ..The first-generation rFVIIa formulation is stable when stored under refrigeration. A new formulation has been developed for storage at room temperature, which may improve patients' access to treatment during bleeding episodes...
  47. ncbi Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome
    Patricia Redecha
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:3453-61. 2008
    ..An antibody specific for human TF that has little impact on coagulation, but potently inhibits TF/Factor VIIa (FVIIa) signaling through PAR2, inhibited aPL-induced neutrophil activation in mice that expressed human TF...
  48. ncbi Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association
    M Margaret Knudson
    Department of Surgery, University of California, San Francisco, USA
    J Am Coll Surg 212:87-95. 2011
    ..We hypothesized that we could describe the setting in which rFVIIa would be most successful in arresting hemorrhage after injury...
  49. ncbi Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
    Blood 117:3199-208. 2011
    Recent studies have shown that factor VIIa (FVIIa) binds to the endothelial cell protein C receptor (EPCR), a cellular receptor for protein C and activated protein C, but the physiologic significance of this interaction is unclear...
  50. ncbi Current status on tissue factor activation of factor VIIa
    Egon Persson
    Haemostasis Biochemistry, Novo Nordisk A S, Måløv, Denmark
    Thromb Res 125:S11-2. 2010
    Free factor VIIa displays a zymogen-like behavior with low intrinsic activity...
  51. ncbi Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients
    Ampaiwan Chuansumrit
    Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Blood Coagul Fibrinolysis 21:354-62. 2010
    ..These results support the safety and potential benefit of rFVIIa for control and prevention of hemorrhage in pediatric patients without congenital hemophilia...
  52. ncbi Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system
    Maisha T Robinson
    Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA
    Stroke 41:1459-63. 2010
    Recombinant Factor VIIa decreases hematoma growth after spontaneous intracerebral hemorrhage (ICH) and rapidly decreases international normalized ratios in patients on warfarin but is also associated with an increased risk for ..
  53. ncbi Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin
    Pancras C Wong
    Thrombosis Research, Bristol Myers Squibb Company, Pennington, New Jersey, USA
    Thromb Haemost 104:302-10. 2010
    ..Under these experimental conditions, a FXIa inhibitor did not prevent TF-induced platelet aggregation...
  54. ncbi The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial?
    Nathaniel McQuay
    Department of Surgery, University of Pennsylvania Health System, Trauma Critica Division, St Luke s Hosptial, USA
    J Neurosurg 111:666-71. 2009
    ..This study evaluates the outcomes of using rFVIIa as first-line therapy in patients with a severe TBI requiring emergent craniotomy that are coagulopathic...
  55. ncbi Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer
    Philippe Zerbib
    Inserm ERI 9, Faculté de Médecine Lille, France Université de Lille 2, EA2693, Lille, France
    J Surg Res 153:239-45. 2009
    ..colorectal cancer (CRC) cells is involved in tumoral angiogenesis and metastasis progression, after binding of factor VIIa (FVIIa) to TF and generation of TF-FVIIa activity...
  56. ncbi Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients
    Carlos V R Brown
    Department of Surgery, University of Texas Southwestern Medical School Austin, University Medical Center Brackenridge Trauma Services, Austin, Texas 78701, USA
    J Trauma 68:348-52. 2010
    ..We hypothesize that rFVIIa would provide an effective and cost efficient means of correcting coagulopathy in patients with traumatic brain injury undergoing emergent craniotomy...
  57. ncbi Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits
    L Chi
    Pfizer Global R and D, Ann Arbor Laboratories, Cardiovascular Pharmacology, Ann Arbor, MI 48105, USA
    J Thromb Haemost 2:85-92. 2004
    ..This model may be useful for evaluating in vivo efficacy of new antithrombotic drugs, particularly TF-FVIIa inhibitors...
  58. ncbi Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials
    Kenneth David Boffard
    Department of Surgery, Johannesburg Hospital, University of the Witwatersrand, South Africa
    J Trauma 59:8-15; discussion 15-8. 2005
    ..and one in penetrating trauma) were conducted simultaneously to evaluate the efficacy and safety of recombinant factor VIIa (rFVIIa) as adjunctive therapy for control of bleeding in patients with severe blunt or penetrating trauma.
  59. ncbi Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven)
    D Viuff
    Hemostasis Pharmacology, Novo Nordisk A S, Novo Nordisk Park, 2760 Måløv, Denmark
    Br J Anaesth 101:324-31. 2008
    ..The haemostatic agent, recombinant activated factor VII (rFVIIa, NovoSeven), may be used to improve haemostasis but potential interactions with different volume expanders are poorly understood...
  60. ncbi The use of recombinant factor VIIa in the treatment of bleeding disorders
    Harold R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
    Blood 104:3858-64. 2004
    Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX...
  61. ncbi A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
    E Santagostino
    Department of Internal Medicine and Dermatology, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation and University of Milan, Milan, Italy
    J Thromb Haemost 4:367-71. 2006
    ..randomized open-label crossover prospective trial was designed to compare the efficacy, safety, and cost of standard and high dosages of recombinant factor VIIa (rFVIIa) for home treatment of hemarthroses in hemophiliacs with inhibitors.
  62. ncbi Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient
    John B Holcomb
    Department of Surgery, University of Texas Health Sciences Center at Houston, Houston, Texas, USA
    Curr Surg 60:423-7. 2003
  63. ncbi Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage
    J D Pickard
    Academic Neurosurgery Unit and Wolfson Brain Imaging Centre, University of Cambridge, UK
    Blood Coagul Fibrinolysis 11:S117-20. 2000
    ..The last patient developed middle cerebral artery branch thrombosis contralateral to the aneurysm. The study is currently suspended pending further investigation...
  64. ncbi Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases
    Pär I Johansson
    Department of Clinical Immunology, University Hospital of Copenhagen, Copenhagen, Denmark
    J Trauma 61:1016-8. 2006
    ..We conclude that rFVIIa may be an effective hemostatic treatment for patients undergoing major wound excision developing life-threatening bleedings...
  65. ncbi Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study
    Lars C Petersen
    Health Care Discovery, Novo Nordisk A S, Måløv and Bagsvaerd, Denmark
    Thromb Res 116:75-85. 2005
    ..Together, these data confirms the notion of poor species compatibility between human FVII and murine TF and emphasizes the requirement for autologous FVIIa in studies on the role of the TF in experimental in vivo pharmacology...
  66. ncbi The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency
    Flora Peyvandi
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione Luigi Villa, IRCCS Maggiore Hospital and University of Milan, 9 20122 Milan, Italy
    Br J Haematol 127:576-84. 2004
    ..Altogether, these defects may explain the severe bleeding symptoms in a patient carrying the FVIIP303T mutation...
  67. ncbi Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1
    Jasimuddin Ahamed
    Department of Immunology, SP258, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    Blood 105:2384-91. 2005
    ....
  68. ncbi Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis
    Svetlana Strukova
    Department of Human and Animal Physiology, Faculty of Biology, Lomonosov Moscow State University, Moscow, 119992, Russia
    Front Biosci 11:59-80. 2006
    Hemostatic serine proteinases-thrombin, Factor VIIa, Factor Xa, play the central role in blood coagulation and thrombosis...
  69. ncbi The tissue factor requirement in blood coagulation
    Thomas Orfeo
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA
    J Biol Chem 280:42887-96. 2005
    ..These observations support the hypothesis that the transient, localized expression of TF is sufficient to sustain a TF-independent procoagulant response as long as flow persists...
  70. ncbi Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery
    Conrad V Bishop
    Department of Cardiothoracic Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    Ann Thorac Surg 81:875-9. 2006
    ..CONCLUSIONS: Our results support the use of rFVIIa as rescue therapy in severe, uncontrollable, nonsurgical, postoperative hemorrhage after cardiac surgery as efficacious and safe...
  71. ncbi The onerous task of comparing treatments in inhibitor patients
    Sam Schulman
    Thromb Haemost 98:710-2. 2007
  72. ncbi Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma
    Fania Szlam
    Department of Anesthesiology, Emory University School of Medicine, 1364 Clifton Rd, NE, Atlanta, GA 30322, USA
    Anesth Analg 106:719-24, table of contents. 2008
    ..We hypothesize that reduced AT concentrations would increase the procoagulant effects of rFVIIa in FVIII-deficient plasma...
  73. ncbi Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders
    Katherine F Croom
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:121-36. 2008
    Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology...
  74. ncbi Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice
    K Ovlisen
    Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 6:969-75. 2008
    ..These result in hemophilic synovitis, an inflammatory and proliferative condition of the joint, which progresses into a chronic degenerative arthritis, hemophilic arthropathy...
  75. ncbi Prolonged in-vivo half-life of factor VIIa by fusion to albumin
    Thomas Weimer
    CSL Behring GmbH, Emil von Behring Strasse 76, 35041 Marburg, Germany
    Thromb Haemost 99:659-67. 2008
    For the treatment of haemophilia patients with inhibitors, recombinant factor VIIa (rFVIIa) is available as a therapeutic option to control bleeding episodes with a good balance of safety and efficacy...
  76. ncbi The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework
    C J Moltzan
    Department of Internal Medicine, St Boniface General Hospital, Winnipeg, Manitoba, Canada
    Transfus Med 18:112-20. 2008
    A review of the recent randomized control trial evidence of the use of recombinant factor VIIa (rFVIIa) in massive bleeding...
  77. ncbi Tissue factor-independent effects of recombinant factor VIIa on hemostasis
    Cees Weeterings
    Department of Clinical Chemistry and Hematology, University Medical Center, Utrecht, The Netherlands
    Semin Hematol 45:S12-5. 2008
    ....
  78. ncbi Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex
    Ivo M B Francischetti
    Section of Medical Entomology, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA
    Blood 99:3602-12. 2002
    ..Recombinant Ixolaris was expressed in insect cells and shown to inhibit factor VIIa (FVIIa)/tissue factor (TF)-induced factor X (FX) activation with an inhibitory concentration of 50% (IC(50)) in ..
  79. ncbi Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis
    Ulla Hedner
    Department of Medicine, University of Lund, Sweden
    Annu Rev Med 59:29-41. 2008
    For hemophilia patients with inhibitors against FVIII or FIX, the development of recombinant factor VIIa (rFVIIa) raises the possibility of a therapeutic alternative whose availability and convenience of treatment are comparable to those ..
  80. ncbi Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding
    Sonia Charbonneau
    Department of Anesthesiology, CHUM, Hopital Notre Dame, Montreal, Canada
    Thromb Haemost 97:296-303. 2007
    ..rHuFVIIa increases thrombosis in a rabbit model of carotid artery injury. The bleeding from hepatic and splenic lesions is not reduced by administration of rHuFVIIa despite a hypercoagulable state confirmed by standard TEG analysis...
  81. ncbi High dose factor VIIa improves clot structure and stability in a model of haemophilia B
    Alisa S Wolberg
    Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, NC 27599 7525, USA
    Br J Haematol 131:645-55. 2005
    ....
  82. ncbi Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy
    R F Johansen
    Department of Biochemistry, Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Aarhus, Skejby, Denmark
    Haemophilia 12:190-7. 2006
    ..However, it seems that WB clotting profile studies at baseline, with ex vivo addition of haemostasis promoting agents, and during treatment may hold the potential to predict the success of treatment...
  83. ncbi Restoring full biological activity to the isolated ectodomain of an integral membrane protein
    Emily K Waters
    Department of Biochemistry, College of Medicine, University of Illinois, Urbana, Illinois 61801, USA
    Biochemistry 45:3769-74. 2006
    ..When soluble tissue factor was tethered to the membrane surface via such metal-chelating lipids, it bound factor VIIa with the same high affinity as wild-type tissue factor, and the resulting factor VIIa-tissue factor complexes ..
  84. ncbi Endotoxaemia induces resistance to activated protein C in healthy humans
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 134:213-9. 2006
    Systemic inflammation activates the tissue factor/factor VIIa complex (TF/FVIIa), leading to a procoagulant state, which may be enhanced by impairment of physiological anticoagulant pathways, such as the protein C system...
  85. ncbi Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells
    Xiaofeng Jiang
    Temple University School of Medicine, Sol Sherry Thrombosis Research Center, Philadelphia, PA 19140, USA
    Thromb Haemost 96:196-201. 2006
    Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factor VIIa (FVIIa)...
  86. ncbi Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist
    M Kjalke
    Haemostasis Biology, Novo Nordisk A S, Måløv, Denmark
    J Thromb Haemost 5:774-80. 2007
    ..Activation of platelets with a combination of collagen and thrombin generates a subpopulation of highly procoagulant 'coated' platelets characterized by high surface expression of fibrinogen and other procoagulant proteins...
  87. ncbi Rapid reversal of anticoagulant bleeding- rFVIIa an option?
    Silva Zupancic-Salek
    J Postgrad Med 53:3-4. 2007
  88. ncbi Factor VIIa: mounting evidence or anecdotal reports
    R MacLaren
    J Postgrad Med 53:4-5. 2007
  89. ncbi Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia
    A C J M de Pont
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 2:65-70. 2004
    ..v. dose rNAPc2 completely blocked endotoxin-induced thrombin generation without affecting the fibrinolytic response. In addition, rNAPc2 attenuated the endotoxin-induced rise in IL-10, without affecting the rises in other cytokines...
  90. ncbi Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor
    A Y Y Lee
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    J Intern Med 254:313-21. 2003
    ....
  91. ncbi Tissue factor and coronary artery disease
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Room F3-236, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Cardiovasc Res 53:313-25. 2002
    ..Specific and non-specific inhibitors of tissue factor or the tissue factor/factor VIIa complex have been developed or identified, and have been tested in experimental studies...
  92. ncbi Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor
    Haining Huang
    Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Biochemistry 42:10619-26. 2003
    Tissue factor (TF), the receptor and cofactor for factor VIIa (VIIa) for cellular initiation of the coagulation protease cascade, drives thrombogenesis, inflammation, tumor cell metastasis, and the lethality of severe sepsis...
  93. ncbi Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex
    John J Parlow
    Department of Medicinal and Combinatorial Chemistry, Pharmacia Corporation, 800 North Lindbergh Boulevard, St Louis, Missouri 63167, USA
    J Med Chem 46:4050-62. 2003
    ..PASP) library synthesis were used to develop a series of pyrazinone inhibitors of the Tissue Factor/Factor VIIa (TF/VIIa) complex...
  94. ncbi Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors
    John J Parlow
    Department of Medicinal and Combinatorial Chemistry, Pharmacia Corporation, 800 North Lindbergh Boulevard, St Louis, Missouri 63167, USA
    J Med Chem 46:4043-9. 2003
    ..A variety of L-amino acid inputs were used to probe the S2 pocket of tissue Factor VIIa enzyme to influence both potency and selectivity...
  95. ncbi Mechanism of action of recombinant factor VIIa
    T Lisman
    Thrombosis and Haemostasis Laboratory, Department of Haematology, Room G03.647, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Thromb Haemost 1:1138-9. 2003
  96. ncbi Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII
    Jenny Goudemand
    Department of Haematology, University Hospital of Lille, France
    Blood Coagul Fibrinolysis 14:505-11. 2003
    ....
  97. ncbi Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders
    Ana Maria Galán
    Hematherapy and Hemostasis Service, Hospital Clinic, Faculty of Medicine, IDIBAPS, Barcelona, Spain
    Transfusion 43:885-92. 2003
    ....
  98. ncbi A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates
    Raffaella Toso
    Department of Biochemistry and Molecular Biology, University of Ferrara, Via Borsari, 46 Ferrara 44100, Italy
    Biochem J 363:411-6. 2002
    ....
  99. ncbi Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor
    J Marcus Lockett
    Research and Pathology Services, Department of Veterans Affairs, Memphis, Tennessee 38104, USA
    Biochemistry 41:4989-97. 2002
    ..Kunitz domains of tissue factor pathway inhibitor (TFPI) are well defined as active site-directed inhibitors of factor VIIa and factor Xa...
  100. ncbi Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 88:627-31. 2002
    ..this pathological response, as revealed by the use of specific inhibitors and antagonists of the tissue factor/factor VIIa pathway...
  101. ncbi Tissue factor - a therapeutic target for thrombotic disorders
    Donald S Houston
    Section of Hematology Oncology, Department of Internal Medicine, University of Manitoba, 675 McDermot Avenue, Winnipeg, Manitoba, R3E 0V9, Canada
    Expert Opin Ther Targets 6:159-74. 2002
    ..Perhaps most intriguing is the use of anti-TF agents locally, which holds the promise of stopping thrombosis at a specific site of injury without the bleeding risk associated with systemic anticoagulation...

Research Grants68

  1. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    ..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
  2. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    ..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
  3. Tissue Factor Pathway Inhibitor Binding Proteins on Endo
    ALAN MAST; Fiscal Year: 2005
    Tissue factor pathway inhibitor (TFPI) rapidly inhibits both factor Xa and the factor VIIa/tissue factor catalytic complex. Thus, it is thought to be the most important inhibitor of the initiation of blood coagulation...
  4. BIOCHEMISTRY OF VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1990
    ..We will study the kinetics of activation of Gla-domainless factor IX by factor XIa/calcium and by factor VIIa/tissue factor/calcium...
  5. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 2001
    ..We will also examine a hypothesis that factor VIIa binds to tissue factor (TF) with a significantly higher affinity than factor VII and that the EGF2 domain of ..
  6. FACTOR XI PHYSIOLOGY AND MOLECULAR BIOLOGY
    David Gailani; Fiscal Year: 2000
    ..In current models of hemostasis, normal coagulation is initiated by the factor VIIa/tissue factor complex, and not through contact activation...
  7. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    ..autoantibodies and autoantibodies to tissue factor pathway inhibitor (TFPI), a critical inhibitor of both factor VIIa/TF and factor Xa...
  8. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1993
    ..Tissue factor pathway inhibitor (TFPI) consists of three kunitz-type domains. The first domain binds to factor VIIa and the second domain binds to factor Xa. The function of the third domain is as yet not clear...
  9. Studies of rHuTPO in ITP and of rVlla in Liver Disease
    David Kuter; Fiscal Year: 2006
    ..undergoing an invasive hepatobiliary procedure is reduced by pre-procedure treatment with FFP or recombinant factor VIIa (rVIIa)...
  10. Deoxyribozymes for Bioorganic Chemistry
    Scott K Silverman; Fiscal Year: 2010
    ..further degradation, and (b) as an approach for in vivo zymogen activation, such as formation of coagulation factor VIIa as a novel approach to treatment of bleeding...
  11. Induction of Tissue Factor by Patient Sera in HUS
    Eric Grabowski; Fiscal Year: 2007
    ..an antibody directed against activated factor X, recombinant-activated protein C, and active site-inhibited r-factor VIIa. A confirmation that shiga toxin and cytokines present in patient sera augment the TF pathway in our model ..
  12. Biochemistry of Normal & Abnormal Variants of Factors IX
    S Bajaj; Fiscal Year: 2006
    This application is based upon the conviction that activation of factor IX (FIX) by the tissue factor/factor VIIa (TF/VIIa) complex represents a key step in the initiation of coagulation by the extrinsic pathway...
  13. BLOOD COAGULATION HOMESTASIS: REGULATION OF TFPI
    Alan Schwartz; Fiscal Year: 2003
    ..inhibitor of coagulation is tissue factor pathway inhibitor (TFPI), which produces feedback inhibition of the factor VIIa/tissue factor complex and directly binds and inhibits factor Xa...
  14. Fluorogenic Assays for Factor Vlla and Tissue Factor
    RICHARD JENNY; Fiscal Year: 2006
    b>Factor VIIa and tissue factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor VIla...
  15. FACTOR X ACTIVATION BY THE EXTRINSIC PATHWAY
    Sriram Krishnaswamy; Fiscal Year: 2000
    ..The enzyme complex (extrinsic Xase) that catalyses this reaction is composed of the serine protease, factor VIIa, and the integral membrane protein, tissue factor, that associate tightly on a cellular or phospholipid surface ..